Celanese Valuation

Is 0HUR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0HUR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0HUR ($73.01) is trading below our estimate of fair value ($192.24)

Significantly Below Fair Value: 0HUR is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0HUR?

Key metric: As 0HUR is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0HUR. This is calculated by dividing 0HUR's market cap by their current earnings.
What is 0HUR's PE Ratio?
PE Ratio7.2x
EarningsUS$1.10b
Market CapUS$8.36b

Price to Earnings Ratio vs Peers

How does 0HUR's PE Ratio compare to its peers?

The above table shows the PE ratio for 0HUR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.3x
CRDA Croda International
30.3x15.1%UK£4.9b
JMAT Johnson Matthey
23.6x28.5%UK£2.5b
VCT Victrex
25.1x37.8%UK£769.6m
TET Treatt
22.1x15.3%UK£250.2m
0HUR Celanese
7.2x14.2%US$8.4b

Price-To-Earnings vs Peers: 0HUR is good value based on its Price-To-Earnings Ratio (7.2x) compared to the peer average (25.3x).


Price to Earnings Ratio vs Industry

How does 0HUR's PE Ratio compare vs other companies in the European Chemicals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0HUR 7.2xIndustry Avg. 17.1xNo. of Companies13PE01224364860+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0HUR is good value based on its Price-To-Earnings Ratio (7.2x) compared to the European Chemicals industry average (17.1x).


Price to Earnings Ratio vs Fair Ratio

What is 0HUR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0HUR PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio7.2x
Fair PE Ratio20.4x

Price-To-Earnings vs Fair Ratio: 0HUR is good value based on its Price-To-Earnings Ratio (7.2x) compared to the estimated Fair Price-To-Earnings Ratio (20.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0HUR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$73.01
US$103.50
+41.8%
17.1%US$150.00US$76.00n/a18
Nov ’25US$125.24
US$146.26
+16.8%
10.8%US$178.00US$120.00n/a19
Oct ’25US$134.77
US$148.40
+10.1%
11.3%US$178.00US$120.00n/a20
Sep ’25US$128.83
US$151.40
+17.5%
11.0%US$180.00US$128.00n/a20
Aug ’25US$137.33
US$160.10
+16.6%
9.9%US$184.00US$130.00n/a20
Jul ’25US$132.24
US$164.00
+24.0%
9.9%US$193.00US$130.00n/a20
Jun ’25US$150.25
US$166.86
+11.1%
9.6%US$197.00US$140.00n/a21
May ’25US$153.59
US$162.23
+5.6%
9.9%US$199.00US$138.00n/a22
Apr ’25US$171.52
US$156.82
-8.6%
10.3%US$195.00US$120.00n/a22
Mar ’25US$153.11
US$156.14
+2.0%
9.5%US$180.00US$120.00n/a22
Feb ’25US$145.06
US$148.23
+2.2%
11.4%US$176.00US$120.00n/a22
Jan ’25US$156.57
US$140.29
-10.4%
10.8%US$169.00US$117.30n/a22
Dec ’24US$141.26
US$135.06
-4.4%
9.4%US$160.00US$110.00n/a22
Nov ’24US$112.59
US$134.56
+19.5%
10.7%US$160.00US$110.00US$125.2422
Oct ’24US$127.29
US$133.06
+4.5%
11.1%US$160.00US$110.00US$134.7722
Sep ’24US$127.92
US$131.73
+3.0%
11.2%US$160.00US$110.00US$128.8322
Aug ’24US$124.78
US$127.14
+1.9%
11.5%US$160.00US$100.00US$137.3322
Jul ’24US$116.28
US$126.00
+8.4%
11.3%US$160.00US$100.00US$132.2423
Jun ’24US$105.55
US$126.76
+20.1%
11.6%US$160.00US$100.00US$150.2522
May ’24US$107.71
US$132.08
+22.6%
11.3%US$160.00US$100.00US$153.5921
Apr ’24US$108.20
US$131.67
+21.7%
11.7%US$160.00US$100.00US$171.5221
Mar ’24US$121.12
US$130.73
+7.9%
12.4%US$160.00US$100.00US$153.1122
Feb ’24US$122.70
US$125.64
+2.4%
15.5%US$160.00US$83.00US$145.0622
Jan ’24US$101.87
US$122.55
+20.3%
16.1%US$160.00US$83.00US$156.5722
Dec ’23US$109.00
US$120.19
+10.3%
15.8%US$160.00US$83.00US$141.2621
Nov ’23US$98.37
US$128.05
+30.2%
19.5%US$180.00US$86.00US$112.5921

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies